Septal closure devices

Information

  • Patent Grant
  • 9017373
  • Patent Number
    9,017,373
  • Date Filed
    Tuesday, December 9, 2003
    20 years ago
  • Date Issued
    Tuesday, April 28, 2015
    9 years ago
Abstract
A closure device for a patent foramen ovale (PFO) has proximal and distal occlusion members for applying compressive forces to tissue on opposite sides of septal defects to help close the defects. The devices are collapsible for delivery and deployment, and can be easily retrieved and redeployed or repositioned if needed.
Description
BACKGROUND OF THE INVENTION

A patent foramen ovale (PFO) as shown in FIG. 1 is a persistent, one-way, usually flap-like opening in the wall between the right atrium 10 and left atrium 12 of the heart. Since left atrial (LA) pressure is normally higher than right atrial (RA) pressure, the flap typically stays closed. Under certain conditions, however, RA pressure can exceed LA pressure, creating the possibility for right to left shunting that can allow blood clots to enter the systemic circulation.


In utero, the foramen ovale serves as a physiologic conduit for right-to-left shunting. After birth, with the establishment of pulmonary circulation, the increased left atrial blood flow and pressure results in functional closure of the foramen ovale. This closure is typically followed by anatomical closure of the two over-lapping layers of tissue, septum primum 14 and septum secundum 16. However, a PFO has been shown to persist in a significant minority of adults.


The presence of a PFO has no therapeutic consequence in otherwise healthy adults. But patients suffering a stroke or TIA in the presence of a PFO and without another cause of ischemic stroke are considered for prophylactic medical therapy to reduce the risk of a recurrent embolic event. These patients can be treated with oral anticoagulants, but such drugs have the potential for adverse side effects such as hemorrhaging, hematoma, and interactions with other drugs. In certain cases, such as when the use of anticoagulation drugs is contraindicated, surgery may be used to suture a PFO closed. Suturing a PFO requires attachment of septum secundum to septum primum with a stitch (continuous or interrupted), which is the common way a surgeon shuts the PFO under direct visualization.


Non-surgical closure of PFOs has become possible with umbrella devices and a variety of other similar mechanical closure designs developed initially for percutaneous closure of atrial septal defects (ASD). These devices allow patients to avoid the potential side effects often associated with anticoagulation therapies.


SUMMARY OF EMBODIMENTS OF THE INVENTION

Embodiments of the present invention are directed to devices for closing septal defects such as PFOs. The closure devices include proximal and distal occlusion members for applying compressive forces to tissue on opposite sides of septal defects to help close the defects. Material patches of a fabric or growth promoting matrix can optionally be applied to the occlusion members to cover the defect and promote tissue ingrowth to improve defect closure. The devices are collapsible for delivery and deployment, and can be easily retrieved and redeployed or repositioned if needed.


These and other features will become apparent from the following detailed description, wherein embodiments of the invention are shown and described by way of illustration. As will be realized, the invention is capable of other and different embodiments and its several details may be capable of modifications in various respects, all without departing from the invention. Accordingly, the drawings and description are to be regarded as illustrative in nature and not in a restrictive or limiting sense.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a cross-sectional view of a portion of the heart illustrating a PFO;



FIGS. 2A and 2B are perspective views of a closure device in accordance with one or more embodiments of the invention in generally collapsed and expanded states, respectively;



FIGS. 3A-3D are side views illustrating deployment of the closure device of FIGS. 2A and 2B in a PFO;



FIGS. 4A and 4B are perspective views of a closure device in expanded and collapsed states, respectively, in accordance with one or more further embodiments of the invention;



FIGS. 5A and 5B are perspective and side views, respectively, illustrating placement of the closure device of FIGS. 4A and 4B in a PFO; and



FIG. 6 is a side view of a closure device in accordance with one or more further embodiments of the invention.





DETAILED DESCRIPTION

Various embodiments of the present invention are directed to methods and devices for closing septal defects such as PFOs. The devices apply compressive forces to compliant tissue on opposite sides of the defect to help close the defect.



FIGS. 2A-2B and 3A-3D generally illustrate a closure device or occluder 20 in accordance with one or more embodiments of the invention. FIGS. 2A and 2B illustrate the device 20 in collapsed and expanded states, respectively. FIGS. 3A-3D illustrate a process of deploying the device 20. The device 20 is radially collapsible into a collapsed configuration (as shown in FIG. 2A) for delivery through a catheter and deployment. Upon deployment, it expands into a predefined expanded configuration (shown generally in FIG. 2B).


The device 20 includes an expandable distal occlusion member 22 and an expandable proximal occlusion member 24 connected to each other. The distal occlusion member 22 (which can be positioned on the left atrial side of a PFO) includes a framework having a central hub 26 and a plurality of outwardly extending elongated struts 28. The free ends of struts 28 can have small loops, ball tips, or otherwise be rounded or configured to reduce trauma. The proximal occlusion member 24 (which can be placed on the right atrial side of the PFO) includes a plurality of wires in the form of loops 29, shown here as overlapping, when the device 20 is in an expanded state. As shown in FIGS. 2A and 2B, loops 29 each extend from a central hub 26 to an end cap 27. The loop forms a plane that is approximately parallel to the tissue it is closing and applies a force that is generally perpendicular to the plane (see also FIG. 5A).


In accordance with some embodiments of the invention, material patches of a fabric or growth promoting matrix can optionally be applied to the occlusion members 22, 24. When the device 20 is deployed, the patches can cover the defect and promote tissue ingrowth to improve defect closure. Numerous biocompatible materials can be used for the patches including, but not limited to, polyester fabrics (such as knitted or woven polyester fabrics), GORE-TEX® (ePTFE), and IVALON® (polyvinyl alcohol foam), naturally occurring tissue scaffolds (such as collagen or acellular tissue matrices), polyurethane, bioresorbable tissue matrices, or electrospun fabric.


The wires forming the device are preferably made of a thermally responsive material having shape memory properties (e.g., nitinol, nitinol alloys, shape memory polymeric materials). The wires could be made of a bioresorbable materials if a tissue scaffold is provided. Suitable shape memory materials can include a first, relatively pliable low temperature phase (mainly R-phase or martensite or both) and a second, relatively rigid high temperature phase (mainly austenite). Such material can, e.g., have a high temperature phase at about body temperature or, more preferably, at temperatures above about 70° F. As is generally known for such materials, the device is collapsed in the R-phase or martensite phase, and then recovers a programmed shape when body heat causes the material in the device to transition to its austenitic phase. It should be understood that these are representative properties that can be varied.


In some respects, this device resembles a vena cava filter as shown in U.S. Pat. No. 4,425,908. A vena cava filter is designed to be inserted into a major vein to prevent a blood clot from entering the lungs, a different purpose from that described here.



FIGS. 3A-3D illustrate deployment of the device 20 for closing a PFO. The device 20 can be delivered to the septal defect in the collapsed state through a standard catheter 30. The catheter 30 is passed through the defect between septum primum 14 and septum secundum 16 as shown in FIG. 3A. The distal occlusion member 22 is then deployed as shown in FIG. 3B. The catheter 30 is retrieved, and the proximal occlusion member 24 is deployed on the proximal part of the defect as shown in FIGS. 3C and 3D. Once deployed, compressive forces are applied by the device 20 to the tissue, causing septum secundum 16 to be drawn toward septum primum 14. A tissue scaffold, if provided, would cause tissue to grow around the scaffold. The device 20 remains in place while the defect can heal to close the hole.


As indicated in FIG. 3D, the struts can just contact tissue at their ends, while the loops generally contact tissue over more of the length of the loops. If desired, the device 20 can be easily retrieved and redeployed or repositioned. The device 20 can be fully or partially pulled back into the delivery sheath from the defect by pulling on end cap 27, which serves as the proximal attachment point of the occluder for use with a recovery type catheter. The device can then be removed completely from the body or redeployed.


Benefits of the device 20 include high fatigue resistance, ability to be used with small diameter delivery sheaths, reduced metal mass, ease of manufacturing, reduced cost, and overall design simplicity.



FIGS. 4A and 4B generally illustrate a closure device or occluder 30 in accordance with one or more further embodiments of the present invention. FIG. 4A illustrates the device 30 in an expanded state when deployed, and FIG. 4B illustrates the device 30 in a generally collapsed state for delivery through a catheter.


The device 30 includes a distal occlusion member 32 (which can be positioned on the left atrial side of a PFO) and a proximal occlusion member 34 (which can be placed on the right atrial side of the PFO). When deployed, the occlusion members 32, 34 apply compressive forces to both sides of a defect, sandwiching the compliant tunnel tissue closed.


Each occlusion member 32, 34 in device 30 includes two collapsible propeller shaped wire petal members. The petals of the two occlusion members are joined by a connecting member 36, which extends into the tunnel defect when the device 30 is deployed. The loops that make up the propeller are shown extending from the central member 36 to end caps 38 and 39. These end caps, like the ones in the other embodiments, can be in a line with the connecting member 36 and can be perpendicular to septum primum and septum secundum if deployed to close a PFO; or they could be not in a line and/or could be skewed relative to a line perpendicular to septum primum and septum secundum if deployed to close a PFO


The petals collapse when the device 30 is pulled at opposite ends as shown in FIG. 4B. This collapsibility allows the device 30 to be elongated for loading into a delivery catheter. Device delivery can be achieved percutaneously by advancing the delivery catheter through the PFO defect. The device 30 can then be deployed. The device can be placed as illustrated, e.g., in FIGS. 5A-5B, with the petals generally oriented in-line with the defect. As shown, a plane defined by a loop is generally parallel to each septum and substantially perpendicular to the force applied by the loop. In FIG. 5A, the left atrial petals are illustrated generally in dashed lines and can be in the same circumferential location.


The device is preferably made from a material having shape memory properties such as Nitinol. This thermally responsive material allows the device petals to attain their desired deployed state geometry once released from the delivery catheter. The petals can be suitably sized to ensure that the device applies sufficient force to achieve defect closure.


The device 30 can close a PFO by applying compressive forces to the compliant flaps of the PFO. In accordance with some embodiments, to further promote hole closure, a fabric or a growth promoting matrix, which may include growth factors or other pharmacological agents or cells, can optionally be added to the petals to promote tissue growth over the device to plug the hole.


The petal design of the device provides wide surface contact with cardiac tissue on both the left and right atrial sides of the PFO defect. Substantial surface area contact by the petals enables generally evenly distributed pressure to be applied to close the PFO. The relatively simple structure of the device 30 allows use of an implant having a reduced metal mass. The device design also facilitates easy manufacture. The device can be made, e.g., by crimping, welding, or otherwise joining the device together in the petal geometry and then annealing.


While the FIG. 4 device 30 has two petals on each of the proximal and distal sides of the device, it should be understood that any number of petals can be used. For example, FIG. 6 illustrates a device 40 having more than two petals on each of the proximal and distal sides of the device. As shown in FIG. 6, the loops on one side are not necessarily at the same circumferential location as loops on the other side.


Having described various embodiments of the present invention, it should be apparent that modifications can be made without departing from the spirit and scope of the invention. The device is described for use with a PFO, but could be used for an atrial septal defect or a ventricular septal defect, in which case the device would typically have a tissue scaffold or other fabric.

Claims
  • 1. An apparatus comprising: a patent foramen ovale (PFO) closure device movable from a collapsed configuration when within a delivery device to a deployed configuration for providing compressive force to a septum primum and a septum secundum, the device further comprising:a central body for extending through the PFO, wherein the central body is elongated and substantially linear and extends along a longitudinal axis of the device,a first end cap, and a second end cap in line with the central body;at least a first wire and a second wire extending through the central body from the first end cap to the second end cap;the first wire and the second wire defining a first occlusion member on a first side of the central body each wire of which extends in a substantially planar manner along the longitudinal axis of the device when in the collapsed configuration and forming a first and a second collapsible loop which are generally perpendicular to the longitudinal axis of the device and which extend in a first plane perpendicular to the central body when in the deployed configuration, and the first and second wire defining a second occlusion member on a second side of the central body, each wire of which extends in a substantially planar manner along the longitudinal axis of the device when in the collapsed configuration and forming a third and a fourth collapsible loop which are generally perpendicular to the longitudinal axis of the device and which extend in a second plane perpendicular to the central body when in the deployed configuration, wherein the first and second plane are generally parallel, wherein each collapsible loop is a single loop extending from the central body to the first or second end cap;wherein moving the first end cap toward the central body moves the first occlusion member from the collapsed configuration to the deployed configuration and moving the second end cap moves the second occlusion member from the collapsed configuration to the deployed configuration;wherein when in the deployed configuration, the first and second occlusion members each cooperate with the central body to apply a generally perpendicular force to overlapping layers of the septum primum and the septum secundum to close the PFO;wherein each of the collapsible loops is independent from one another; andwherein further, the first wire and the second wire extending through the central body from the first end cap to the second end cap extend in a substantially planar manner along the longitudinal axis of the device when in the collapsed configuration within the delivery device.
  • 2. The apparatus of claim 1, wherein the device includes nitinol.
  • 3. The apparatus of claim 1, wherein the device includes a shape memory polymeric material.
  • 4. The apparatus of claim 1, wherein the device is made from a shape memory material with properties such that the device, when delivered into a body, has a phase transition and assumes the deployed configuration.
  • 5. The apparatus of claim 1, wherein the device is retrievable, redeployable, and repositionable.
  • 6. A method comprising delivering the PFO closure device of claim 5 through a catheter to a PFO.
  • 7. The apparatus of claim 1, further comprising a material over the first and second loops for promoting tissue ingrowth.
  • 8. The apparatus of claim 7, wherein the loops are made of a bioresorbable material.
  • 9. A method comprising delivering the PFO closure device of claim 8 through a catheter to a PFO.
  • 10. A method comprising delivering the PFO closure device of claim 8 through a catheter to a PFO, and drawing the device back into the catheter.
  • 11. The apparatus of claim 7, further comprising a material over the third and fourth loops for promoting tissue ingrowth.
  • 12. A method comprising delivering the PFO closure device of claim 7 through a catheter to a PFO.
  • 13. A method comprising delivering the PFO closure device of claim 1 through a catheter to a PFO.
  • 14. The method of claim 13, further comprising aligning a first axis defined by the first and second loops when in the deployed configuration with a longitudinal axis defined by the septum primum and septum secundum, wherein the first axis extends from a point on the first loop furthest from the central body to a point on the second loop furthest from the central body.
  • 15. The method of claim 14, further comprising aligning a second axis defined by the third and fourth loops when in the deployed configuration with the longitudinal axis defined by the septum primum and septum secundum, wherein the second axis extends from a point on the third loop furthest from the central body to a point on the fourth loop furthest from the central body.
  • 16. A method comprising delivering the PFO closure device of claim 1 through a catheter to a PFO, wherein the device includes a shape memory material.
  • 17. The apparatus of claim 1, wherein each loop is petal shaped.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority from provisional Ser. No. 60/431,924, filed Dec. 9, 2002, which is incorporated herein by reference.

US Referenced Citations (318)
Number Name Date Kind
3824631 Burstein et al. Jul 1974 A
3874388 King et al. Apr 1975 A
3875648 Bone Apr 1975 A
3924631 Mancusi Dec 1975 A
4006747 Kronenthal et al. Feb 1977 A
4007743 Blake Feb 1977 A
4149327 Hammer et al. Apr 1979 A
4425908 Simon Jan 1984 A
4610674 Suzuki et al. Sep 1986 A
4626245 Weinstein Dec 1986 A
4693249 Schenck et al. Sep 1987 A
4696300 Anderson Sep 1987 A
4710181 Fuqua Dec 1987 A
4710192 Liotta et al. Dec 1987 A
4738666 Fuqua Apr 1988 A
4832055 Palestrant May 1989 A
4836204 Landymore et al. Jun 1989 A
4840623 Quackenbush Jun 1989 A
4902508 Badylak et al. Feb 1990 A
4915107 Rebuffat et al. Apr 1990 A
4917089 Sideris Apr 1990 A
4921479 Grayzel May 1990 A
4956178 Badylak et al. Sep 1990 A
5021059 Kensey et al. Jun 1991 A
5037433 Wilk et al. Aug 1991 A
5041129 Hayhurst et al. Aug 1991 A
5049131 Deuss Sep 1991 A
5078736 Behl Jan 1992 A
5106913 Yamaguchi et al. Apr 1992 A
5108420 Marks Apr 1992 A
5149327 Oshiyama et al. Sep 1992 A
5163131 Row et al. Nov 1992 A
5167363 Adkinson et al. Dec 1992 A
5167637 Okada et al. Dec 1992 A
5171259 Inoue Dec 1992 A
5176659 Mancini Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5222974 Kensey et al. Jun 1993 A
5226879 Ensminger et al. Jul 1993 A
5236440 Hlavacek Aug 1993 A
5245023 Peoples et al. Sep 1993 A
5245080 Aubard et al. Sep 1993 A
5250430 Peoples et al. Oct 1993 A
5257637 El Gazayerli Nov 1993 A
5275826 Badylak et al. Jan 1994 A
5282827 Kensey et al. Feb 1994 A
5284488 Sideris Feb 1994 A
5304184 Hathaway et al. Apr 1994 A
5312341 Turi May 1994 A
5312435 Nash et al. May 1994 A
5316262 Koebler May 1994 A
5320611 Bonutti et al. Jun 1994 A
5334217 Das Aug 1994 A
5350363 Goode et al. Sep 1994 A
5354308 Simon et al. Oct 1994 A
5364356 Hofling Nov 1994 A
5411481 Allen et al. May 1995 A
5413584 Schulze May 1995 A
5417699 Klein et al. May 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5451235 Lock et al. Sep 1995 A
5453099 Lee et al. Sep 1995 A
5478353 Yoon Dec 1995 A
5480353 Garza, Jr. Jan 1996 A
5480424 Cox Jan 1996 A
5486193 Bourne et al. Jan 1996 A
5507811 Koike et al. Apr 1996 A
5534432 Peoples et al. Jul 1996 A
5540712 Kleshinski et al. Jul 1996 A
5562632 Davila et al. Oct 1996 A
5577299 Thompson et al. Nov 1996 A
5601571 Moss Feb 1997 A
5603703 Elsberry et al. Feb 1997 A
5618311 Gryskiewicz Apr 1997 A
5620461 Muijs Van De Moer et al. Apr 1997 A
5626599 Bourne et al. May 1997 A
5634936 Linden et al. Jun 1997 A
5649950 Bourne et al. Jul 1997 A
5649959 Hannam et al. Jul 1997 A
5663063 Peoples et al. Sep 1997 A
5683411 Kavteladze et al. Nov 1997 A
5690674 Diaz Nov 1997 A
5693085 Buirge et al. Dec 1997 A
5702421 Schneidt et al. Dec 1997 A
5709707 Lock et al. Jan 1998 A
5713864 Verkaart Feb 1998 A
5717259 Schexnayder Feb 1998 A
5720754 Middleman et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5733337 Carr, Jr. et al. Mar 1998 A
5741297 Simon Apr 1998 A
5772641 Wilson Jun 1998 A
5776162 Kleshinski Jul 1998 A
5776183 Kanesaka et al. Jul 1998 A
5797960 Stevens et al. Aug 1998 A
5800516 Fine et al. Sep 1998 A
5810884 Kim Sep 1998 A
5820594 Fontirroche et al. Oct 1998 A
5823956 Roth et al. Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5853420 Chevillon et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855614 Stevens et al. Jan 1999 A
5861003 Latson et al. Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5879366 Shaw et al. Mar 1999 A
5893856 Jacob et al. Apr 1999 A
5902287 Martin May 1999 A
5902319 Daley May 1999 A
5904703 Gilson May 1999 A
5919200 Stambaugh et al. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5928250 Koike et al. Jul 1999 A
5944691 Querns et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5955110 Patel et al. Sep 1999 A
5976174 Ruiz Nov 1999 A
5980505 Wilson Nov 1999 A
5989268 Pugsley, Jr. et al. Nov 1999 A
5993475 Lin et al. Nov 1999 A
5993844 Abraham et al. Nov 1999 A
5997575 Whitson et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6019753 Pagan Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6027519 Stanford Feb 2000 A
6030007 Bassily et al. Feb 2000 A
6056760 Koike et al. May 2000 A
6071998 Muller et al. Jun 2000 A
6077291 Das Jun 2000 A
6077880 Castillo et al. Jun 2000 A
6079414 Roth Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6096347 Geddes et al. Aug 2000 A
6106913 Scardino et al. Aug 2000 A
6113609 Adams Sep 2000 A
6117159 Huebsch et al. Sep 2000 A
6126686 Badylak et al. Oct 2000 A
6132438 Fleischman et al. Oct 2000 A
6143037 Goldstein et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6165183 Kuehn et al. Dec 2000 A
6165204 Levinson et al. Dec 2000 A
6168588 Wilson Jan 2001 B1
6171329 Shaw et al. Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6174330 Stinson Jan 2001 B1
6183443 Kratoska et al. Feb 2001 B1
6187039 Hiles et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6190357 Ferrari et al. Feb 2001 B1
6197016 Fourkas et al. Mar 2001 B1
6199262 Martin Mar 2001 B1
6206895 Levinson Mar 2001 B1
6206907 Marino et al. Mar 2001 B1
6214029 Thill et al. Apr 2001 B1
6217590 Levinson Apr 2001 B1
6221092 Koike et al. Apr 2001 B1
6227139 Nguyen et al. May 2001 B1
6228097 Levinson et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6245080 Levinson Jun 2001 B1
6245537 Williams et al. Jun 2001 B1
6261309 Urbanski Jul 2001 B1
6265333 Dzenis et al. Jul 2001 B1
6270515 Linden et al. Aug 2001 B1
6277138 Levinson et al. Aug 2001 B1
6277139 Levinson et al. Aug 2001 B1
6287317 Makower et al. Sep 2001 B1
6290674 Roue et al. Sep 2001 B1
6299635 Frantzen Oct 2001 B1
6306150 Levinson Oct 2001 B1
6306424 Vyakarnam et al. Oct 2001 B1
6312443 Stone Nov 2001 B1
6312446 Huebsch et al. Nov 2001 B1
6315791 Gingras et al. Nov 2001 B1
6316262 Huisman et al. Nov 2001 B1
6319263 Levinson Nov 2001 B1
6322548 Payne et al. Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6334872 Termin et al. Jan 2002 B1
6342064 Koike et al. Jan 2002 B1
6344048 Chin et al. Feb 2002 B1
6344049 Levinson et al. Feb 2002 B1
6346074 Roth Feb 2002 B1
6348041 Klint Feb 2002 B1
6352552 Levinson et al. Mar 2002 B1
6355052 Neuss et al. Mar 2002 B1
6356782 Sirimanne et al. Mar 2002 B1
6358238 Sherry Mar 2002 B1
6364853 French et al. Apr 2002 B1
6371904 Sirimanne et al. Apr 2002 B1
6375625 French et al. Apr 2002 B1
6375671 Kobayashi et al. Apr 2002 B1
6379342 Levinson Apr 2002 B1
6379368 Corcoran et al. Apr 2002 B1
6387104 Pugsley, Jr. et al. May 2002 B1
6398796 Levinson Jun 2002 B2
6402772 Amplatz et al. Jun 2002 B1
6419669 Frazier et al. Jul 2002 B1
6426145 Moroni Jul 2002 B1
6436088 Frazier et al. Aug 2002 B2
6440152 Gainor et al. Aug 2002 B1
6450987 Kramer Sep 2002 B1
6460749 Levinson et al. Oct 2002 B1
6482224 Michler et al. Nov 2002 B1
6488706 Solymar Dec 2002 B1
6494846 Margolis Dec 2002 B1
6494888 Laufer et al. Dec 2002 B1
6508828 Akerfeldt et al. Jan 2003 B1
6514515 Williams Feb 2003 B1
6548569 Williams et al. Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6551344 Thill Apr 2003 B2
6585719 Wang Jul 2003 B2
6585755 Jackson et al. Jul 2003 B2
6596013 Yang et al. Jul 2003 B2
6599448 Ehrhard, Jr. et al. Jul 2003 B1
6610764 Martin et al. Aug 2003 B1
6623506 McGuckin et al. Sep 2003 B2
6623508 Shaw et al. Sep 2003 B2
6623518 Thompson et al. Sep 2003 B2
6626936 Stinson Sep 2003 B2
6629901 Huang Oct 2003 B2
6666861 Grabek Dec 2003 B1
6669722 Chen et al. Dec 2003 B2
6689589 Huisman et al. Feb 2004 B2
6712804 Roue et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6726696 Houser et al. Apr 2004 B1
6828357 Martin et al. Dec 2004 B1
6838493 Williams et al. Jan 2005 B2
6867247 Williams et al. Mar 2005 B2
6867248 Martin et al. Mar 2005 B1
6867249 Lee et al. Mar 2005 B2
6921410 Porter Jul 2005 B2
7097653 Freudenthal et al. Aug 2006 B2
20010010481 Blanc et al. Aug 2001 A1
20010014800 Frazier et al. Aug 2001 A1
20010025132 Alferness et al. Sep 2001 A1
20010034537 Shaw et al. Oct 2001 A1
20010034567 Allen et al. Oct 2001 A1
20010037129 Thill Nov 2001 A1
20010039435 Roue et al. Nov 2001 A1
20010039436 Frazier et al. Nov 2001 A1
20010041914 Frazier et al. Nov 2001 A1
20010041915 Roue et al. Nov 2001 A1
20010044639 Levinson Nov 2001 A1
20010049492 Frazier et al. Dec 2001 A1
20020010481 Jayaraman Jan 2002 A1
20020019648 Akerfeldt et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020022860 Borillo et al. Feb 2002 A1
20020026208 Roe et al. Feb 2002 A1
20020029048 Miller Mar 2002 A1
20020032459 Horzewski et al. Mar 2002 A1
20020032462 Houser et al. Mar 2002 A1
20020034259 Tada Mar 2002 A1
20020035374 Borillo et al. Mar 2002 A1
20020043307 Ishida et al. Apr 2002 A1
20020049457 Kaplan et al. Apr 2002 A1
20020052572 Franco et al. May 2002 A1
20020058989 Chen et al. May 2002 A1
20020077555 Schwartz Jun 2002 A1
20020095174 Tsugita et al. Jul 2002 A1
20020096183 Stevens et al. Jul 2002 A1
20020099389 Michler et al. Jul 2002 A1
20020099390 Kaplan et al. Jul 2002 A1
20020103492 Kaplan et al. Aug 2002 A1
20020107531 Schreck et al. Aug 2002 A1
20020111537 Taylor et al. Aug 2002 A1
20020111637 Kaplan et al. Aug 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020128680 Pavlovic Sep 2002 A1
20020129819 Feldman et al. Sep 2002 A1
20020164729 Skraly et al. Nov 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020183786 Girton Dec 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020183823 Pappu Dec 2002 A1
20020198563 Gainor et al. Dec 2002 A1
20030004533 Dieck et al. Jan 2003 A1
20030023266 Borillo et al. Jan 2003 A1
20030028213 Thill et al. Feb 2003 A1
20030045893 Ginn Mar 2003 A1
20030050665 Ginn Mar 2003 A1
20030055455 Yang et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030059640 Marton et al. Mar 2003 A1
20030065379 Babbs et al. Apr 2003 A1
20030100920 Akin et al. May 2003 A1
20030113868 Flor et al. Jun 2003 A1
20030120337 Van Tassel et al. Jun 2003 A1
20030139819 Beer et al. Jul 2003 A1
20030171774 Freudenthal et al. Sep 2003 A1
20030191495 Ryan et al. Oct 2003 A1
20030195530 Thill Oct 2003 A1
20030204203 Khairkhahan et al. Oct 2003 A1
20040044361 Frazier et al. Mar 2004 A1
20040073242 Chanduszko Apr 2004 A1
20040133236 Chanduszko Jul 2004 A1
20040176799 Chanduszko et al. Sep 2004 A1
20040210301 Obermiller Oct 2004 A1
20040234567 Dawson Nov 2004 A1
20050025809 Hasirci et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050113868 Devellian May 2005 A1
20050267523 Devellian et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050288786 Chanduszko Dec 2005 A1
20060122647 Callaghan et al. Jun 2006 A1
20060265004 Callaghan et al. Nov 2006 A1
20060271089 Alejandro et al. Nov 2006 A1
20070010851 Chanduszko et al. Jan 2007 A1
20070167981 Opolski Jul 2007 A1
Foreign Referenced Citations (56)
Number Date Country
9413645 Oct 1994 DE
0362113 Apr 1990 EP
0474887 Mar 1992 EP
0 839 549 May 1998 EP
0 861 632 Sep 1998 EP
1 013 227 Jun 2000 EP
1 046 375 Oct 2000 EP
1 222 897 Jul 2002 EP
WO 9601591 Jan 1996 WO
WO 9625179 Aug 1996 WO
WO 9631157 Oct 1996 WO
WO-9807375 Feb 1998 WO
WO-9808462 Mar 1998 WO
WO-9816174 Apr 1998 WO
WO-9829026 Jul 1998 WO
WO-9851812 Nov 1998 WO
WO-9905977 Feb 1999 WO
WO-9818864 Apr 1999 WO
WO-9918862 Apr 1999 WO
WO-9918864 Apr 1999 WO
WO-9918870 Apr 1999 WO
WO-9918871 Apr 1999 WO
WO-9930640 Jun 1999 WO
WO-9966846 Dec 1999 WO
WO 0027292 May 2000 WO
WO 0044428 Aug 2000 WO
WO-0108600 Feb 2001 WO
WO-0119256 Mar 2001 WO
WO-0121247 Mar 2001 WO
WO-0128432 Apr 2001 WO
WO-0130268 May 2001 WO
0149185 Jul 2001 WO
WO-0178596 Oct 2001 WO
WO-0193783 Dec 2001 WO
WO-0217809 Mar 2002 WO
WO 0224106 Mar 2002 WO
WO-03024337 Mar 2003 WO
WO-03053493 Jul 2003 WO
WO-03059152 Jul 2003 WO
WO-03063732 Aug 2003 WO
WO 03077733 Sep 2003 WO
WO-03082076 Oct 2003 WO
WO-03103476 Dec 2003 WO
WO-2004032993 Apr 2004 WO
WO-2004043266 May 2004 WO
WO-2004043508 May 2004 WO
WO-2004052213 Jun 2004 WO
WO-2005006990 Jan 2005 WO
WO-2005018728 Mar 2005 WO
WO-2005027752 Mar 2005 WO
WO-2005074813 Aug 2005 WO
WO-2005092203 Oct 2005 WO
WO-2005110240 Nov 2005 WO
WO-2005112779 Dec 2005 WO
WO-2006036837 Apr 2006 WO
WO-2006102213 Sep 2006 WO
Non-Patent Literature Citations (55)
Entry
Nat'l Aeronautics and Space Administration, “55-Nitinol—The Alloy with a Memory: Its Physical Metallurgy, Properties, and Applications,” A Report, pp. 24-25.
Kimura, A., et al., “Effects of Neutron Irradiation on the Transformation Behavior in Ti-Ni Alloys,” Abstract, Proceedings of the Int'l Conf. on Mariensitic Transformations (1992) pp. 935-940.
Ramanathan, G., et al., “Experimental and Computational Methods for Shape Memory Alloys,” 15th ASCE Engineering Mechanics Conf., Jun. 2-5, 2003.
Shabalovskaya, S., “Surface, corrosion and biocompatibility aspects of Nitinol as an implant material,” Bio-Medical materials and Engineering, (2002) vol. 12, pp. 69-109.
Uchil, J. “Shape Memory Alloys—Characterization Techniques,” Pramana—Journal of Physics, (2002) vol. 58, Nos. 5 & 6, pp. 1131-1139.
Stöckel, “Nitinol Medical Devices and Implants,” SMST-2000 Conference Proceedings, 2001, pp. 531-541.
SMST-2000, “Proceedings of the International Conference on Shape Memory and Superelastic Technologies,” Apr. 30 to May 4, 2000, Asilomar Conference Center.
Ruiz et al. “The Puncture Technique: A New Method for Transcatheter Closure of Patent Foramen Ovale,” Catheterization and Cardiovascular Interventions 53, Wiley-Liss, Inc., 2001, pp. 369-372.
International Search Report, International Application No. PCT/US03/17390, mailed on Oct. 6, 2003, 4 pgs.
Athanasion, T., “Coronary Artery Bypass with the Use of a Magnetic Distal Anastomotic Device: Surgical Technique and Preliminary Experience,” The Heart Surgery Forum #2004-1024, 2004, 4 pgs.
Bachthaler, M. et al., “Corrosion of Tungsten Coils After Peripheral Vascular Embolization Theraphy: Influence on Outcome and Tungsten Load”, Catherization and Cardiovascular Interventions, vol. 62, pp. 380-384, 2004.
European Examination Report, European Application No. 04781644.2, mailed Aug. 23, 2007 (3 Pages).
European Search Report, European Application No. 03729663.9, mailed Feb. 20, 2008 (3 Pages).
Falk, V., “Facilitated Endoscopic Beating Heart Coronary Artery Bypass Grafting Using a Magentic Coupling Device,” Journal of Thoracic and Cardiovascular Surgery, vol. 126,(5), pp. 1575-1579.
Filsoufi, F., et al., “Automated Distal Coronary Bypass with a Novel Magnetic Coupler (MVP system),” J. Thoracic and Cardiovascular Surgery, vol. 127(1), pp. 185-192.
International Search Report, International Application No. PCT/US02/40850 mailed Jun. 19, 2003 (4 pgs).
International Search Report, International Application No. PCT/US03/01050, mailed Jul. 8, 2003 (1 pg).
International Search Report, International Application No. PCT/US03/09051, mailed Sep. 29, 2003 (2 pgs).
International Search Report, International Application No. PCT/US03/17715, mailed Mar. 24, 2004 (2 pgs).
International Search Report, International Application No. PCT/US03/32133, mailed Apr. 22, 2004 (1 pg).
International Search Report, International Application No. PCT/US03/34003 mailed Oct. 3, 2004 (4 pgs).
International Search Report, International Application No. PCT/US03/35479, mailed Apr. 14, 2004 (2 pgs).
International Search Report, International Application No. PCT/US03/35998 mailed Jun. 16, 2004 (5 pgs).
International Search Report, International Application No. PCT/US03/39253, mailed Apr. 19, 2004 (4 pgs).
International Search Report, International Application No. PCT/US04/022643, mailed Mar. 31, 2005 (2 pgs).
International Search Report, International Application No. PCT/US04/026998, mailed Apr. 22, 2005 (5 pgs).
International Search Report, International Application No. PCT/US04/029978, mailed Jan. 26, 2005 (3 pgs).
International Search Report, International Application No. PCT/US05/006703, mailed Jul. 25, 2005 (3 pgs).
International Search Report, International Application No. PCT/US05/013705 mailed Aug. 4, 2005 (4 pgs).
International Search Report, International Application No. PCT/US05/015382, mailed Oct. 6, 2005 (4 pgs).
International Search Report, International Application No. PCT/US07/065546, mailed Oct. 29, 2007. 4 pages.
International Search Report, International Application No. PCT/US2007/065526, mailed Aug. 8, 2007 (5 pgs).
International Search Report, International Application No. PCT/US2007/065541, mailed Aug. 7, 2007 (4 pgs).
International Search Report, International Application No. PCT/US97/14822, mailed Feb. 20, 1998 (2 pgs).
International Search Report, International Application No. PCT/US97/17927, mailed Feb. 10, 1998 (1 pg).
Isotalo, T. et al., “Biocompatibility Testing of a New Bioabsorbable X-Ray Positive SR-PLA 96/4 Urethral Stent”, The Journal of Urology, vol. 163, pp. 1764-1767, Nov. 1999.
Klima, U., “Magnetic Vascular Port in Minimally Invasive Direct Coronary Artery Bypass Grafting,” Circulation, 2004, II-55-II-60.
Meier, MD, Bernhard, et al., “Contemporary Management of Patent Foramen Ovale,” American Heart Association, Inc., Circulation, 2003, vol. 107, pp. 5-9.
Parviainen, M. et al., “A New Biodegradable Stent for the Pancreaticojejunal Anastomosis After Pancreaticoduodenal Resection: In Vitro Examination and Pilot Experiences in Humans”, Pancreas, vol. 21, No. 1, pp. 14-21, 2000.
Ruddy, A.C. et al., “Rheological, Mechanical and Thermal Behaviour of Radipaque Filled Polymers”, Polymer Processing Research Centre, School of Chemical Engineering, Queen's University of Belfast , 5 pages.
Vaajanen, A. et al., “Expansion and Fixation Properties of a New Braided Biodegradable Urethral Stent: An Experimental Study in the Rabbit”, The Journal of Urology, vol. 169, pp. 1771-1174, Mar. 2003.
European Examination Report, European Application No. 03729663.9, mailed Jul. 16, 2008 (5 Pages).
European Examination Report, European Application No. 03731562.9, mailed Jul. 18, 2008 (3 Pages).
European Examination Report, European Application No. 03779297.5, mailed Mar. 15, 2007 (6 Pages).
International Search Report and Written Opinion, International Patent Application No. PCT/US06/41255, mailed Jun. 13, 2008 (6 pgs).
International Search Report and Written Opinion, International Patent Application No. PCT/US08/59429, mailed Sep. 5, 2008 (9 pgs).
International Search Report for International Patent Application No. PCT/AU03/00759, filed Jun. 19, 2003.
International Search Report, International Application No. PCT/US05/34276, mailed Oct. 9, 2007.
International Search Report, International Application No. PCT/US2006/009978, mailed Jul. 13, 2006 (2 pgs).
Kimura, A.., et al., “Effects of Neutron Irradiation on the Transformation Behavior in Ti—Ni Alloys,” Abstract, Proceedings of the Int'l Conf. on Mariensitic Transformations, 1992, pp. 935-940.
Nat'l Aeronautics and Space Administration, “55-Nitinol—The Alloy with a Memory: Its Physical Metallurgy, Properties, ans Applications,” NASA Report, pp. 24-25.
Ramanathan, G., et al., “Experimental and Computational Methods for Shape Memory Alloys,” 15th ASCE Engineering Mechanics Conference, Jun. 2-5, 2002.
Shabalovskaya, S., “Surface Corrosion and Biocompatibility Aspects of Nitinol as and Implant Material,” Bio-Medical Materials and Engineering, 2002, vol. 12, pp. 69-109.
Uchil, J., “Shape Memory Alloys—Characterization Techniques,” Pramana—Journal of Physics, 2002 vol. 58 (5)(6), pp. 1131-1139.
European Search Report from EP 11 17 6128.
Related Publications (1)
Number Date Country
20040176799 A1 Sep 2004 US
Provisional Applications (1)
Number Date Country
60431924 Dec 2002 US